semaglutide heart disease and the Heart: Focus on Their Love–Hate Relationship In patients with cardiometabolic #HFpEF,

SN and SC analyzed and interpreted the data

Research suggests that the peptide may enhance sodium reabsorption in the kidney, leading to increased fluid retention

Current Retatrutide clinical trials show promising results, especially in terms of weight loss

Consistent therapeutic levels are paramount for achieving the desired clinical outcomes, which include: Improved Glycemic Control: For individuals with type 2 diabetes, stable semaglutide levels help regulate blood sugar by stimulating insulin release when blood glucose is high, suppressing glucagon secretion, and slowing gastric emptying

GLP-1s are known to cause a delay in gastric emptying, as noted in the label of each of our GLP-1 RA medications